The effect of GA treatment on spontaneous colitis in C3H.IL10-/- mice GA treatment by daily subcutaneous injections, 2 mg/mouse, for 1 month was administered to a 3-month-old male C3H/HeJBir IL-10-/- mice with established disease. A vehicle control group (two mice injected daily with 0.1 ml of PBS) in experiment 1 exhibited disease manifestations identical to the control untreated group. Experiments 1, 2, and 3 were performed 5, 10, and 12 months, respectively, after the transfer of the C3H.IL10-/- colony from SPF to conventional conditions. n indicates the number of animals in a group.
Treatment | n | Hemocult | Histology | |
|---|---|---|---|---|
| Experiment 1 | Control (no treatment) | 3 | 1.2 ± 0.5 | 4.0 ± 1.0 |
| GA (daily 2 mg/mouse) | 6 | 0.1 ± 0.3* | 1.0 ± 1.6* | |
| Experiment 2 | Control (no treatment) | 2 | 1 ± 0.0 | 6.0 ± 0.0 |
| GA (daily 2 mg/mouse) | 3 | 0.1 ± 0.3* | 4.3 ± 0.6* | |
| Experiment 3 | Control (no treatment) | 5 | 1.3 ± 0.2 | 7.6 ± 1.3 |
|
| GA (daily 2 mg/mouse) | 8 | 0.1 ± 0.1* | 6.2 ± 1.0 |
↵* , significant decrease in GA-treated mice versus untreated mice in the same experiment (P < 0.05)